The increasing prevalence of diabetes is a major health problem. The detection and treatment of prediabetes can delay the onset of diabetes and presents an important diabetes prevention strategy.
Prediabetes is a high-risk state for developing diabetes. 1 Recent data have shown that in developed countries more than a third of adults have prediabetes. 2, 3 Detection of prediabetes is a fundamental strategy to keep people from transitioning to diabetes. [1] [2] [3] [4] [5] Once detected, prediabetes should be acknowledged with a treatment plan (metformin or intense lifestyle intervention) to prevent or slow the transition to diabetes. 6 However, it is unclear whether primary care physicians diagnose prediabetes and adjust the treatment plan in light of HbA 1c results.
Methods
We analyzed data from the 2012 National Ambulatory Medical Care Survey (NAMCS), a national probability sample survey of ambulatory medical care visits to office-based physicians that allows for national estimates regarding US medical care. 7 We focused on individuals ages 45 and older because that age group is consistent with the 2012 American Diabetes Association screening recommendations for prediabetes. 1 We included results of HbA 1c tests ordered within the 90 days preceding the sampled visit because that result would still be considered current for decision making at that visit. The sampled visits were to a general/family medicine or internal medicine provider. A total of 518 visits were available for analysis, and when these visits are weighted for the population and the analysis controlled for the complex sampling design, they represent 1,167,004 office-based ambulatory medical care visits.
Prediabetes was defined as HbA 1c within the range of 5.7% to 6.4%. 1 Individuals were considered to have diagnosed prediabetes if 1 of the 3 diagnosis fields was the International Classification of Diseases, 9th Revision, code for prediabetes (790.29).
To account for the complex sampling design of the NAMCS, we used SAS software version 9.4 (SAS Institute, Cary, NC) for all analyses. We examined the characteristics of patients in both the full sample and the sample of patients with a positive test for prediabetes. We conducted logistic regression to examine the impact of HbA 1c level and other patient characteristics on receiving treatment for prediabetes among individuals with a current prediabetes test result and prediabetes. HbA 1c level was categorized as low prediabetes (5.7% to 5.9%) and high prediabetes (6.0% to 6.4%). Listwise deletion was used in cases with missing data.
In analyzing NAMCS, the National Center for Health Statistics states that any frequencies with fewer than 30 respondents are considered unreliable and should not be used to make population estimates. Estimates that are considered unreliable are noted in the text when appropriate. Table 1 indicates characteristics of individuals with no previous diagnosis of diabetes and a current HbA 1c test. Rates were similar between men and women, with 40.0% of women and 36.5% of men having prediabetes. The most commonly occurring (in 16.3%) primary diagnosis for patients with prediabetes was hypertensive disease (International Classification of Diseases, 9th Revision, codes 401 to 405). Although the results of the HbA 1c test were available to the participating physician, who recorded his or her actions in the NAMCS, the number of patients who received a diagnosis of prediabetes was too small to allow reliable estimates to be produced (the estimate was 0.92%).
Results
There were no significant differences in receiving treatments based on HbA 1c level. Of patients with an HbA 1c level between 5.7% and 5.9%, 22.6% received treatment for prediabetes, compared with 23.5% of patients with an HbA 1c level between 6.0% and 6.4% (P ϭ .91). Table 2 shows the results of the logistic regression model for receiving treatment. No variables included in the model were significant, including the HbA 1c test results.
Discussion
Considering the large proportion of patients with an HbA 1c test that is consistent with prediabetes, the number of patients diagnosed was too small to make a reliable population estimate, and three fourths of those with prediabetes were not provided with an appropriate treatment plan. This lack of diagnosis should be considered in light of the fact that the most common primary diagnosis for that visit was hypertension, a common comorbid condition with diabetes. Our study does not explain why physicians did not record a prediabetes diagnosis and offer patients effective interventions to delay the onset of diabetes. Potential explanations include lack of awareness of the potential effect of interventions in reducing diabetes risk, lack of access to providers of dietary and exercise advice, and therapeutic inertia. There is also a possible concern among some clinicians that diagnosing prediabetes overmedicalizes a condition that is not a disease. 8 For some patients with other morbidities, addressing prediabetes may not have been regarded as a priority. Further, it is possible that an artifact of the NAMCS data, which limits the physician to 3 diagnoses, may have created an undercount of diagnoses of prediabetes because there was not enough room to list it if it was considered the 4th or higher diagnosis. Finally, although we were evaluating ambulatory practice in the United States, the American Diabetes Association's HbA 1c range as a definition of prediabetes used in this study is not universally adopted around the world. 9 As such, glucose tolerance testing may be an advisable further evaluation step to clarify the diagnostic status of individuals with HbA 1c of 5.7% to 6.4%. Nevertheless, the finding that most patients with confirmed prediabetes do not receive appropriate care suggests that the approach of primary care toward prediabetes needs to change if we are to effectively prevent diabetes.
